Balance Sheet And Shareholder ReturnsThe company has an enviable balance sheet position of ~1x net debt:EBITDA, which increases optionality to return cash to shareholders via buybacks.
Earnings GrowthAptarGroup remains well-positioned to deliver on a multiyear period of double-digit earnings growth, led by secular drivers within Pharma and increased operating leverage in Packaging.
Pharma Segment PerformancePharma continues to be led by strength in the RX channel, which along with growth in Consumer and Active Materials offsets a tough comparison that weighed on Injectables.